Metraipolis › archive › dc_4f8f765bee87

Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer — Europe PMC PMID:41369006

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41369006
DOI
10.1080/07853890.2025.2583551
License (as archived)
solo-consultazione
Archived
2026-11-07T18:41:58.474Z
SHA-256 of the archived text
6a0683429ff43fcf6f65798c28ec6aa7745cb5e6b22e58117f13b59694c5f2b3
Stable URL of this page
https://metraipolis.com/documento/dc_4f8f765bee87

How to cite

Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer — Europe PMC PMID:41369006 — Europe PMC (en), https://europepmc.org/article/MED/41369006 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4f8f765bee87 (Metraipolis archive dc_4f8f765bee87, sha256 6a0683429ff43fcf6f65798c28ec6aa7745cb5e6b22e58117f13b59694c5f2b3)
BibTeX
@misc{dc4f8f765bee87,
  title = {Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer — Europe PMC PMID:41369006},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41369006},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4f8f765bee87; sha256 6a0683429ff43fcf6f65798c28ec6aa7745cb5e6b22e58117f13b59694c5f2b3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41369006. Agents can read the archived copy with the MCP tool read_document.